A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Domestic market and developing countries will need doses of Indian vaccines
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
